Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Charles River Laboratories International Inc.
Headquarters: Wilmington, MA, United States of America
Website: http://www.criver.com
Year Founded: 1947
Status: Public
Industry Sector: CommercialServices
CEO: James C. Foster
Number Of Employees: 20,100
Enterprise Value: $12,093,120,760
PE Ratio: 666.82
Exchange/Ticker 1: NYSE:CRL
Exchange/Ticker 2: N/A
Latest Market Cap: $8,747,259,904
BioCentury | Oct 19, 2024
Finance
Biotech restructurings show signs of slowing
Temporary respite or reflection of a stabilizing sector?
BioCentury | Aug 14, 2023
Management Tracks
Gardner named CEO of Flagship’s Ampersand
Plus: Brian Powl joins Kura as CCO, and updates from BioNTech, Allogene, CG and more
BioCentury | May 5, 2023
Management Tracks
Walensky resigning as CDC director
Plus: Riva to lead Transgene as CEO and updates from Aerami, Ginkgo and Tris
BioCentury | Dec 3, 2022
Finance
Dec. 2 Quick Takes: Liminatus heads for NASDAQ via SPAC deal
Plus: FDA clears Beam’s CD7-targeting CAR T for clinical trial, and updates from GSK, Theratechnologies, PictorLabs and more
BioCentury | Apr 26, 2022
Management Tracks
Nektar to cut 70% of staff; Nuyten, Northcott to depart
Plus Carisma names co-founder Klichinsky as CSO and updates from Caravella, Reeve Foundation, Evonetix and more
BioCentury | Mar 28, 2022
Management Tracks
Asif Ali to join Protagonist as CFO
Plus new CMO at Avenge Bio, new CEO at
BioCentury | Dec 18, 2021
Deals
Dec. 17 Quick Takes: Ipsen, Genfit advancing former NASH candidate in PBC
Plus: ALS play Amylyx seeking NASDAQ listing and updates from Novartis, Pfizer-BioNTech, IN8bio and more
BioCentury | Nov 6, 2021
Deals
Nov. 5 Quick Takes: $103M raise to support bit.bio’s cell coding tech
Plus Alphabet launches digital biology venture, IO Biotech’s IPO, setbacks for Deciphera, Calithera and more
BioCentury | May 17, 2021
Deals
May 17 Quick Takes: Antengene adds CD73 inhibitor to pipeline via Calithera deal; plus Aadi, Apellis, Charles River-Vigene, FDA and Sanofi-GSK
Seven months after its $360 million IPO on the Hong Kong stock exchange, Shanghai-based Antengene Corp. Ltd. (HKEX:6996) is building out its pipeline with exclusive, worldwide development and
BioCentury | Mar 25, 2020
Product Development
CROs might be the engine that keeps preclinical research moving during COVID-19
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Items per page:
1 - 10 of 130